EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers

Andreas Meier, Spyros Papapetropoulos, Andrew Marsh, Kelly Neelon, David Stiles, Ryan O'Mara, Evan A Thackaberry, Marco Colonna, Raj Rajagovindan

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70033 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Andreas Meier und 8 weiteren Autor:innen. Beteiligte Einrichtung: Formerly Vigil Neuroscience, Inc., Watertown, Massachusetts, USA. Hauptthemen laut MEDLINE: Membrane Glycoproteins, Receptors, Immunologic, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vigil Neuroscience Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of iluzanebart, a fully human monoclonal antibody TREM2 (triggering receptor expressed on myeloid cells 2) agonist, after single‐ (SAD) and multiple‐ascending‐dose (MAD) administration.

Methods

Healthy adult volunteers ( N = 136) received intravenous placebo or iluzanebart 1–60 mg/kg (SAD) or 10–60 mg/kg (MAD) followed by serial pharmacokinetics and safety assessments. Safety assessments included adverse events (AEs), vital signs, electrocardiograms, and clinical laboratory evaluations. Pharmacokinetics were assessed through noncompartmental analysis. The study also included open‐label cohorts (3, 10, 20, 40, 60 mg/kg SAD; 10, 20, 40 mg/kg MAD) for cerebrospinal fluid (CSF) collection for exploratory pharmacodynamic biomarker analysis.

Results

Iluzanebart was safe and well tolerated following single and multiple doses of up to 60 mg/kg. Most AEs were mild and resolved spontaneously. The most frequently reported AE was pruritus. No serious AEs or investigational product–related clinically meaningful changes in vital signs, electrocardiograms, or laboratory assessments were reported. Iluzanebart serum exposure was related to dose, with a 29‐day half‐life that is supportive of monthly dosing and confirmed central nervous system (CNS) exposure (≈0.15% CSF‐to‐serum ratio). Durable and dose‐dependent target engagement, evidenced by marked reductions in soluble TREM2 and increased soluble CSF1R (colony‐stimulating factor 1 receptor) and osteopontin/SPP1 (secreted phosphoprotein 1) levels in CSF, was observed, indicating that iluzanebart changes microglial activity following single and repeat dosing.

Interpretation

Iluzanebart demonstrated favorable safety, tolerability, pharmacokinetics, and pharmacological activity in the CNS, supporting further clinical development for adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane GlycoproteinsReceptors, ImmunologicAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedHumansAdultMaleFemaleHealthy VolunteersMiddle AgedYoung AdultDose-Response Relationship, DrugAdolescent

Stichwörter der Autor:innen

CSF‐1 receptorTREM2adult‐onset leukoencephalopathy with axonal spheroids and pigmented gliailuzanebartmicroglia

Substanzen

Membrane GlycoproteinsReceptors, ImmunologicTREM2 protein, humanAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Formerly Vigil Neuroscience, Inc., Watertown, Massachusetts, USA.
  • Vigil Neuroscience, Inc., Watertown, Massachusetts, USA.
  • Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA.

Förderung

  • Vigil Neuroscience Inc

Zitieren

APA

Meier, A., Papapetropoulos, S., Marsh, A., Neelon, K., Stiles, D., O'Mara, R., Thackaberry, E. A., Colonna, M., & Rajagovindan, R. (2025). Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70033

Vancouver

Meier A, Papapetropoulos S, Marsh A, Neelon K, Stiles D, O'Mara R, et al. Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70033

BibTeX
@article{Meier2025,
  author = {Meier, Andreas and Papapetropoulos, Spyros and Marsh, Andrew and Neelon, Kelly and Stiles, David and O'Mara, Ryan and Thackaberry, Evan A and Colonna, Marco and Rajagovindan, Raj},
  title = {Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70033}
}
Kostenlos starten →